Condition: C3 Glomerulopathy · Membranoproliferative Glomerulonephritis · Complement Abnormality · Sponsor: Region Skane
The aim of this cross-over trial is to assess aliskiren, a direct renin inhibitor, as a novel treatment to block complement activation in the kidneys and thereby attenuate renal disease and stabilize or improve kidney function and compare it to the currently used treatment with the angiotensin converting enzyme inhibitor, enalapril, in patients with the complement-mediated renal disease C3 glomerulopathy. Patients will be randomized to one or the other treatment for the first 6 months and then switch to the other treament for the following 2.5 years. Treatment will continue for altogether 3 years for each patient.
This description comes directly from the study's public registry record.
Diana Karpman, MD PhD · +46-46-2220747 · diana.karpman@med.lu.se
Zivile Bekassy, MD PhD · zivile.bekassy@med.lu.se
Always discuss trial participation with your own doctor first.
| Sahlgrenska Hospital | Gothenburg, Sweden | Not Yet Recruiting |
| Region Skåne Skåne Universitetssjukhus | Lund, Sweden | Recruiting |
| Karolinska Hospital | Stockholm, Sweden | Not Yet Recruiting |
| Akademiska sjukhuset | Uppsala, Sweden | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04183101